From d28f2ffbdde6230249a6312e695e916edd1e0da9 Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Mon, 16 Mar 2026 13:04:47 +0000 Subject: [PATCH] extract: 2026-02-01-glp1-patent-cliff-generics-global-competition Pentagon-Agent: Ganymede --- ...et cost impact inflationary through 2035.md | 12 ++++++++++++ ...patent-cliff-generics-global-competition.md | 18 +++++++++++++++++- 2 files changed, 29 insertions(+), 1 deletion(-) diff --git a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md index 329db7879..cc1d46892 100644 --- a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md +++ b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md @@ -35,6 +35,18 @@ The Cell Press review characterizes GLP-1s as marking a 'system-level redefiniti MA plans' near-universal prior authorization creates administrative friction that may worsen the already-poor adherence rates for GLP-1s. PA requirements ensure only T2D-diagnosed patients can access, effectively blocking obesity-only coverage despite FDA approval. This access restriction compounds the chronic-use economics challenge by adding administrative barriers on top of existing adherence problems. + +### Additional Evidence (challenge) +*Source: [[2026-02-01-glp1-patent-cliff-generics-global-competition]] | Added: 2026-03-16* + +International generic competition beginning in 2026 will compress prices far faster than the 'inflationary through 2035' timeline assumes. Canada's semaglutide patents expired January 4, 2026, with Sandoz, Apotex, and Teva filing immediately. Brazil opens March 2026. China has 17+ Phase 3 generic candidates targeting $40-$50/month pricing. India patents expire March 2026. Even accounting for US regulatory delays (patents to 2031-2032), international price arbitrage and compounding pharmacy pressure will accelerate US price compression. At $40-$50/month (95% below current US pricing), GLP-1s become unambiguously cost-effective under any payment model, potentially shifting the inflection point where volume growth no longer offsets price compression to before 2030. + + +### Additional Evidence (extend) +*Source: [[2026-02-01-glp1-patent-cliff-generics-global-competition]] | Added: 2026-03-16* + +Oral Wegovy launched January 2026 at $149-$299/month (Medicare deal: $245/month), representing 50-75% reduction from injectable pricing. This creates a two-tier market structure where oral formulations compress prices even before generic competition, and the oral/injectable price differential may drive faster adoption than the chronic-use-only model predicts. Orforglipron (Eli Lilly non-peptide oral GLP-1) could be approved Q2 2026, adding competitive pressure. + --- Relevant Notes: diff --git a/inbox/archive/2026-02-01-glp1-patent-cliff-generics-global-competition.md b/inbox/archive/2026-02-01-glp1-patent-cliff-generics-global-competition.md index bbeeccda9..74ae486c5 100644 --- a/inbox/archive/2026-02-01-glp1-patent-cliff-generics-global-competition.md +++ b/inbox/archive/2026-02-01-glp1-patent-cliff-generics-global-competition.md @@ -7,9 +7,13 @@ date: 2026-02-01 domain: health secondary_domains: [internet-finance] format: article -status: unprocessed +status: enrichment priority: medium tags: [glp-1, generics, patent-cliff, global-competition, drug-pricing, market-structure] +processed_by: vida +processed_date: 2026-03-16 +enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"] +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content @@ -50,3 +54,15 @@ Overview of the GLP-1 generic competition landscape as patents begin expiring in PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]] WHY ARCHIVED: Price trajectory is the key variable the existing claim depends on — if prices decline faster than assumed, the "inflationary through 2035" conclusion may be wrong EXTRACTION HINT: Focus on the price trajectory and its implications for cost-effectiveness under different payment models, especially the international competition pressure + + +## Key Facts +- Semaglutide US patents extend to 2031-2032 +- Canada semaglutide patents expired January 4, 2026 +- Brazil generic semaglutide competition opens March 2026 +- India semaglutide patents expire March 2026 +- China has 17+ generic semaglutide candidates in Phase 3 trials +- Oral Wegovy launched January 2026 at $149-$299/month +- Medicare oral Wegovy deal: $245/month +- Sandoz, Apotex, and Teva filed for Canadian generic semaglutide immediately after patent expiry +- Biomm + Biocon (India) preparing generic semaglutide for Brazil market